[1] |
Jaffe E, Harris N, Stein H, et al. Pathology and genetics of tumours of haematopoietic and lymphoid tissues[M]. Lyon: Iarc Press, 2001: 171-5.
|
[2] |
Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001[J]. Blood, 2006, 107(1): 265-76. doi: 10.1182/blood-2005-06-2508
|
[3] |
唐晓钰, 庞辉. 结外弥漫大 B 细胞淋巴瘤的发病及生存研究进展[J]. 医学综述, 2016, 22(15): 2972-4. doi: 10.3969/j.issn.1006-2084.2016.15.017
|
[4] |
李小秋, 李甘地, 高子芬, 等. 中国淋巴瘤亚型分布: 国内多中心性病例10002例分析[J]. 诊断学理论与实践, 2012, 11(2): 111-5.
|
[5] |
张静, 蔡映云. 呼吸困难鉴别诊断的临床思维[J]. 中国呼吸与危重监护杂志, 2004, 3(6): 14-5.
|
[6] |
Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling[J]. Adv Immunol, 2005, 87(2): 163-208.
|
[7] |
Rosenwald A, Staudt LM. Gene expression profiling of diffuse large B-cell lymphoma[J]. Leuk Lymphoma, 2003, 44(sup3): S41-7. doi: 10.1080/10428190310001623775
|
[8] |
Hartmann S, Döring C, Jakobus C, et al. Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma--endpoints of a spectrum of one disease[J]. PLoS One, 2013, 8(11): e78812-20. doi: 10.1371/journal.pone.0078812
|
[9] |
Boudová L, Torlakovic E, Delabie J, et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma[J]. Blood, 2003, 102(10): 3753-8. doi: 10.1182/blood-2003-02-0626
|
[10] |
Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma[J]. Proc Natl Acad Sci USA, 2003, 100(17): 9991-6. doi: 10.1073/pnas.1732008100
|
[11] |
Zucca E, Cavalli F. Extranodal lymphomas[J]. Ann Oncol, 2000, 11(Suppl 3): 219-22. doi: 10.1093/annonc/11.suppl_3.219
|
[12] |
王彦丽, 王炳元, 阙雪梅. 东北地区原发结外非霍奇金淋巴瘤81 例分析[J]. 中国误诊学杂志, 2011, 11(21): 5244-9.
|
[13] |
娄丽丽, 岑溪南, 欧晋平, 等. 236例原发性结外淋巴瘤临床和病理分析[J]. 中国实验血液学杂志, 2014, 22(1): 85-92.
|
[14] |
de Sousa LA, Esperto H, Santos L, et al. Primary mediastinal (thymic) B-cell lymphoma presenting as cutaneous vasculitis[J]. BMJ Case Rep, 2015, 16(21): 1309-20.
|
[15] |
Miyahara N, Eda R, Umemori Y, et al. Pulmonary lymphoma of large B-cell type mimicking Wegener's granulomatosis[J]. Intern Med, 2001, 40(8): 786-90. doi: 10.2169/internalmedicine.40.786
|
[16] |
Mertosylu H, Muallaoglu S, Besen AA, et al. Primary extranodal non-Hodgkin, s lymphoma: clinicopathological features, survival and treatment outcome in two cancer central of southern Turkey[J]. Res Art, 2014, 15(10): 7202-11.
|
[17] |
Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma[J]. N Engl J Med, 1993, 328(14): 1002-6. doi: 10.1056/NEJM199304083281404
|
[18] |
Forero A, Lobuglio AF. History of antibody therapy for non-Hodgkin's lymphoma[J]. Semin Oncol, 2003, 30(6 Suppl 17): 1-5.
|
[19] |
Martelli M, Ferreri AJ, Agostinelli C, et al. Diffuse large B-cell lymphoma[J]. Crit Rev Oncol Hematol, 2013, 87(2): 146-71. doi: 10.1016/j.critrevonc.2012.12.009
|
[20] |
Van Den Neste E, Schmitz N, Mounier N, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study[J]. Bone Marrow Transplant, 2017, 52(2): 216-21. doi: 10.1038/bmt.2016.213
|
[21] |
Jurinovic V, Kridel R, Staiger AM, et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy[J]. Blood, 2016, 128(8): 1112-20. doi: 10.1182/blood-2016-05-717355
|
[22] |
Telio D, Fernandes K, Ma C, et al. Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors[J]. Leuk Lymphoma, 2012, 53(5): 836-41. doi: 10.3109/10428194.2011.643404
|
[23] |
Elstrom RL, Martin P, Ostrow K, et al. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies[J]. Clin Lymphoma Myeloma Leuk, 2010, 10(3): 192-6. doi: 10.3816/CLML.2010.n.030
|
[24] |
Seshadri T, Stakiw J, Pintilie M, et al. Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy[J]. Hematology, 2008, 13(5): 261-6. doi: 10.1179/102453308X343527
|
[25] |
Nagle SJ, Woo K, Schuster SJ, et al. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era[J]. Am J Hematol, 2013, 88(10): 890-4. doi: 10.1002/ajh.23524
|
[26] |
Lukenbill J, Hill B. Relapsed/refractory diffuse large B-cell lymphoma: review of the management of transplant-eligible patients[J]. Leuk Lymphoma, 2015, 56(2): 293-300. doi: 10.3109/10428194.2014.910660
|
[27] |
Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy[J]. Cancer Res, 2007, 67(3): 1270-81. doi: 10.1158/0008-5472.CAN-06-2184
|
[28] |
Laursen MB, Falgreen S, Bødker JS, et al. Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma[J]. Exp Hematol, 2014, 42(11): 927-38. doi: 10.1016/j.exphem.2014.07.263
|
[29] |
Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase Ⅱ study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma[J]. J Clin Oncol, 2013, 31(17): 2103-9. doi: 10.1200/JCO.2012.46.5203
|
[30] |
青晓艳, 姚文秀, 徐义全, 等. 原发结外弥漫大B细胞淋巴瘤的免疫分型及其与预后的关系[J]. 中华临床医师杂志: 电子版, 2012, 6(17): 5073-8.
|